<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34652564</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2107-0180</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of drug metabolism and pharmacokinetics</Title>
          <ISOAbbreviation>Eur J Drug Metab Pharmacokinet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree<sup>TM</sup>) in Healthy Adult Subjects.</ArticleTitle>
        <Pagination>
          <StartPage>69</StartPage>
          <EndPage>79</EndPage>
          <MedlinePgn>69-79</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13318-021-00729-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Viloxazine extended-release (viloxazine ER) capsules (Qelbree<sup>TM</sup>) is a novel nonstimulant recently approved as a treatment for attention-deficit/hyperactivity disorder in children and adolescents. Here, we determined whether the pharmacokinetics of viloxazine are impacted by consuming the capsule contents sprinkled on applesauce rather than an intact capsule, and the effect of a high-fat meal on the pharmacokinetics of viloxazine ER.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This was a randomized, open-label, crossover, three-treatment, three-period study in healthy adults using orally administered single-dose viloxazine ER 200 mg capsules. Subjects consumed: (1) an intact capsule after a 10-h fast (control condition); (2) the capsule contents sprinkled on one tablespoon of applesauce; and (3) an intact capsule with a standard high-fat meal. Blood samples were collected for 48 h post-dosing. Relative bioavailability analyses were performed to assess the impact of each test condition against the control condition (intact capsule, fasting). The absence of an impact was indicated if the 90% confidence interval (CI) for the least-squares geometric mean ratio (LSGMR) of maximal concentration (C<sub>max</sub>), the area under the concentration-time curve from time 0 to the last measurable concentration time (AUC<sub>last</sub>), and the area under the concentration-time curve from time 0 to infinity (AUC<sub>inf</sub>) were within the predetermined no-difference limits of 80-125%.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 27 enrolled subjects, 25 were included in the pharmacokinetic analysis. The LSGMR (90% CI) for viloxazine ER sprinkled vs. intact were 90.10% (83.35-97.40) for C<sub>max</sub>, 93.71% (89.09-98.57) for AUC<sub>last</sub>, and 95.37% (89.80-101.28) for AUC<sub>inf</sub>. The LSGMR (90% CI) for viloxazine ER consumed in the fed state vs. fasting state were 90.86% (84.05-98.21) for C<sub>max</sub>, 89.68% (85.26-94.33) for AUC<sub>last</sub>, and 92.35% (86.96-98.07) for AUC<sub>inf</sub>. The 90% CIs of the LSGMRs were within the predetermined no-difference limits of 80-125%. Viloxazine ER was well tolerated, with most adverse events reported as mild.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data suggest that viloxazine ER can be consumed sprinkled on applesauce or as intact capsules with or without meals without significantly changing its pharmacokinetics.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kosheleff</LastName>
            <ForeName>Alisa R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adeojo</LastName>
            <ForeName>Lilian W</ForeName>
            <Initials>LW</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Odebo</LastName>
            <ForeName>Oyinkansola</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liranso</LastName>
            <ForeName>Tesfaye</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwabe</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, USA. anasser@supernus.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Eur J Drug Metab Pharmacokinet</MedlineTA>
        <NlmUniqueID>7608491</NlmUniqueID>
        <ISSNLinking>0378-7966</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002214">Capsules</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002214" MajorTopicYN="N">Capsules</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059305" MajorTopicYN="Y">Diet, High-Fat</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018565" MajorTopicYN="Y">Food-Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>A. Nasser, Z. Wang, A Kosheleff, L. Adeojo, O. Odebo, and T. Liranso are employees of Supernus Pharmaceuticals, Inc. S. Schwabe was an employee of Supernus Pharmaceuticals, Inc. at the time of this work. </CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>12</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34652564</ArticleId>
        <ArticleId IdType="pmc">PMC8752548</ArticleId>
        <ArticleId IdType="doi">10.1007/s13318-021-00729-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s13318-021-00729-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC: American Psychiatric Publishing; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Danielson ML, et al.  Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212. doi: 10.1080/15374416.2017.1417860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15374416.2017.1417860</ArticleId>
            <ArticleId IdType="pmc">PMC5834391</ArticleId>
            <ArticleId IdType="pubmed">29363986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–499. doi: 10.1007/s13311-012-0135-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-012-0135-8</ArticleId>
            <ArticleId IdType="pmc">PMC3441936</ArticleId>
            <ArticleId IdType="pubmed">22976615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessler RC, et al.  The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163(4):716–723. doi: 10.1176/ajp.2006.163.4.716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.2006.163.4.716</ArticleId>
            <ArticleId IdType="pmc">PMC2859678</ArticleId>
            <ArticleId IdType="pubmed">16585449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds K, et al.  Prevalence of psychiatric disorders in US older adults: findings from a nationally representative survey. World Psychiatry. 2015;14(1):74–81. doi: 10.1002/wps.20193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wps.20193</ArticleId>
            <ArticleId IdType="pmc">PMC4329900</ArticleId>
            <ArticleId IdType="pubmed">25655161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stein DJ, et al.  Lifetime prevalence of psychiatric disorders in South Africa. Br J Psychiatry. 2008;192(2):112–117. doi: 10.1192/bjp.bp.106.029280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.bp.106.029280</ArticleId>
            <ArticleId IdType="pmc">PMC2718689</ArticleId>
            <ArticleId IdType="pubmed">18245026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alegría M, et al.  Prevalence of psychiatric disorders across Latino subgroups in the United States. Am J Public Health. 2007;97(1):68–75. doi: 10.2105/AJPH.2006.087205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/AJPH.2006.087205</ArticleId>
            <ArticleId IdType="pmc">PMC1716243</ArticleId>
            <ArticleId IdType="pubmed">17138910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly J, D’Cruz G, Wright D. Patients with dysphagia: experiences of taking medication. J Adv Nurs. 2010;66(1):82–91. doi: 10.1111/j.1365-2648.2009.05145.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2648.2009.05145.x</ArticleId>
            <ArticleId IdType="pubmed">19968724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430(1–2):197–206. doi: 10.1016/j.ijpharm.2012.04.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2012.04.022</ArticleId>
            <ArticleId IdType="pubmed">22525080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardiner P, Dvorkin L. Promoting medication adherence in children. Am Fam Physician. 2006;74(5):793–798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16970023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eli Lilly and Company, LLC. Strattera (atomoxetine): prescribing information. Indianapolis: Eli Lilly and Company, LLC; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Shire US Inc. Intuniv (guanfacine extended-release): prescribing information. Lexington: Shire US Inc.; 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Cutler AJ, Mattingly GW. Beyond the pill: new medication delivery options for ADHD. CNS Spectr. 2017;22(6):463–474. doi: 10.1017/S1092852916000936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1092852916000936</ArticleId>
            <ArticleId IdType="pubmed">28683846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osterberg L, Urquhart J, Blaschke T. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88(4):457–459. doi: 10.1038/clpt.2010.171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/clpt.2010.171</ArticleId>
            <ArticleId IdType="pubmed">20856243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrison A, Stauffer ME, Kaufman AS. Relationship between adherence rate threshold and drug ‘forgiveness’. Clin Pharmacokinet. 2017;56(12):1435–1440. doi: 10.1007/s40262-017-0552-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40262-017-0552-2</ArticleId>
            <ArticleId IdType="pubmed">28470545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornish P. “Avoid the crush”: hazards of medication administration in patients with dysphagia or a feeding tube. Can Med Assoc J. 2005;172(7):871–872. doi: 10.1503/cmaj.050176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.050176</ArticleId>
            <ArticleId IdType="pmc">PMC554868</ArticleId>
            <ArticleId IdType="pubmed">15795404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davit BM, Conner DP.  Food effects on drug bioavailability: implications for new and generic drug development. In: Krishna R, Yu L, editors. Biopharmaceutics applications in drug development. Boston, MA: Springer; 2008. pp. 317–335.</Citation>
        </Reference>
        <Reference>
          <Citation>Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213–224. doi: 10.1007/s10865-007-9147-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10865-007-9147-y</ArticleId>
            <ArticleId IdType="pmc">PMC2868342</ArticleId>
            <ArticleId IdType="pubmed">18202907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–590. doi: 10.2165/00003088-200544060-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003088-200544060-00002</ArticleId>
            <ArticleId IdType="pubmed">15910008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Raga J, Knecht C, de Alvaro R. Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2015;11:1359. doi: 10.2147/NDT.S65735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/NDT.S65735</ArticleId>
            <ArticleId IdType="pmc">PMC4455846</ArticleId>
            <ArticleId IdType="pubmed">26064054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer L. Difficulty with pill swallowing is blamed for non-compliance. Paediatr Nurs. 2009;21(6):13–14. doi: 10.7748/paed.21.6.13.s18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7748/paed.21.6.13.s18</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santer M, et al.  Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers’ views. BMC Pediatr. 2014;14(1):1–10. doi: 10.1186/1471-2431-14-63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2431-14-63</ArticleId>
            <ArticleId IdType="pmc">PMC3984727</ArticleId>
            <ArticleId IdType="pubmed">24593304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, et al.  A phase 3, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended release) in the treatment of ADHD in school-age children. Clin Ther. 2020;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2020.05.021</ArticleId>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized controlled trial. Clin Ther. 2021;43(4):684–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, et al.  A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370–380. doi: 10.1097/JCP.0000000000001404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0000000000001404</ArticleId>
            <ArticleId IdType="pmc">PMC8244935</ArticleId>
            <ArticleId IdType="pubmed">34181360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, et al.  A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharm Bull. 2021;51(2):43–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8146561</ArticleId>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals Inc. Supernus announces positive results from phase III study for SPN-812 in adults with ADHD. 2020. https://ir.supernus.com/news-releases/news-release-details/supernus-announces-positive-results-phase-iii-study-spn-812-0.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285–1300. doi: 10.1080/00498254.2020.1767319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00498254.2020.1767319</ArticleId>
            <ArticleId IdType="pubmed">32394778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Center for Drug Evaluation and Research. Food-effect bioavailability and fed bioequivalence studies: guidance for industry. Silver Spring: Center for Drug Evaluation and Research; 2002.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, et al.  Impact of paroxetine, a strong CYP2D6 inhibitor, on SPN-812 (viloxazine extended-release) pharmacokinetics in healthy adults. Clin Pharmacol Drug Dev. 2021 doi: 10.1002/cpdd.948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpdd.948</ArticleId>
            <ArticleId IdType="pmc">PMC8597116</ArticleId>
            <ArticleId IdType="pubmed">33943033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tulloch SJ, et al.  SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22(11):1405–1415. doi: 10.1592/phco.22.16.1405.33687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1592/phco.22.16.1405.33687</ArticleId>
            <ArticleId IdType="pubmed">12432966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pentikis HS, et al.  Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry. 2002;41(4):443–449. doi: 10.1097/00004583-200204000-00017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004583-200204000-00017</ArticleId>
            <ArticleId IdType="pubmed">11931601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faison SL, et al.  Pharmacokinetics of co-administered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharm. 2021;41(2):155–162. doi: 10.1097/JCP.0000000000001361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0000000000001361</ArticleId>
            <ArticleId IdType="pmc">PMC7919699</ArticleId>
            <ArticleId IdType="pubmed">33587403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faison SL, et al.  Pharmacokinetics of co-administered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults. Clin Drug Investig. 2020;41:149–159. doi: 10.1007/s40261-020-00992-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40261-020-00992-6</ArticleId>
            <ArticleId IdType="pmc">PMC7886742</ArticleId>
            <ArticleId IdType="pubmed">33368026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marquis J, et al.  Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. Int J Clin Pharm. 2013;35(6):1130–1136. doi: 10.1007/s11096-013-9836-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11096-013-9836-2</ArticleId>
            <ArticleId IdType="pubmed">23963541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiele JT, et al.  Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013;69(4):937–948. doi: 10.1007/s00228-012-1417-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00228-012-1417-0</ArticleId>
            <ArticleId IdType="pubmed">23052416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghuman JK, et al.  Behavioral training for pill-swallowing difficulties in young children with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14(4):601–611. doi: 10.1089/cap.2004.14.601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2004.14.601</ArticleId>
            <ArticleId IdType="pubmed">15662153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HS, et al. Sprinkle formulations—a review of commercially available products. Asian J Pharm Sci. 2020;15(3):292–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7327757</ArticleId>
            <ArticleId IdType="pubmed">32636948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RA, Rathbone MJ.  Overview of controlled release mechanisms. In: Seipmann J, Siegel RA, Rathbone MJ, editors. Fundamentals and applications of controlled release drug delivery. Boston, MA: Springer; 2012. pp. 19–43.</Citation>
        </Reference>
        <Reference>
          <Citation>Cattaneo D, et al.  Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. Antimicrob Agents Chemother. 2012;56(12):6132–6136. doi: 10.1128/AAC.00942-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00942-12</ArticleId>
            <ArticleId IdType="pmc">PMC3497176</ArticleId>
            <ArticleId IdType="pubmed">22964253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker C. Pharmacological treatments for ADHD. Prog Neurol Psychiatry. 2013;17(4):11–20. doi: 10.1002/pnp.289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pnp.289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer T, et al.  Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–432. doi: 10.1097/00004583-199604000-00008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004583-199604000-00008</ArticleId>
            <ArticleId IdType="pubmed">8919704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals, Inc. Qelbree (viloxazine extended-release capsules): prescribing information. Rockville, MD: Supernus Pharmaceuticals, Inc.; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, et al.  Population pharmacokinetics of viloxazine extended-release capsules in pediatric subjects with attention deficit/hyperactivity disorder. J Clin Pharmacol. 2021 doi: 10.1002/jcph.1940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcph.1940</ArticleId>
            <ArticleId IdType="pubmed">34269426</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
